These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 29654026

  • 21. Risk factors for healthcare-acquired urinary tract infections caused by multi-drug resistant microorganisms.
    Djordjević ZM, Folić MM, Gavrilović J, Janković SM.
    Srp Arh Celok Lek; 2016; 144(9-10):490-6. PubMed ID: 29652464
    [Abstract] [Full Text] [Related]

  • 22. Bacteremic Urinary Tract Infection Caused by Multidrug-Resistant Enterobacteriaceae Are Associated With Severe Sepsis at Admission: Implication for Empirical Therapy.
    Lee YC, Hsiao CY, Hung MC, Hung SC, Wang HP, Huang YJ, Wang JT.
    Medicine (Baltimore); 2016 May; 95(20):e3694. PubMed ID: 27196480
    [Abstract] [Full Text] [Related]

  • 23. Cost of Gram-negative resistance.
    Evans HL, Lefrak SN, Lyman J, Smith RL, Chong TW, McElearney ST, Schulman AR, Hughes MG, Raymond DP, Pruett TL, Sawyer RG.
    Crit Care Med; 2007 Jan; 35(1):89-95. PubMed ID: 17110877
    [Abstract] [Full Text] [Related]

  • 24. Identification and pretherapy susceptibility of pathogens in patients with complicated urinary tract infection or acute pyelonephritis enrolled in a clinical study in the United States from November 2004 through April 2006.
    Peterson J, Kaul S, Khashab M, Fisher A, Kahn JB.
    Clin Ther; 2007 Oct; 29(10):2215-21. PubMed ID: 18042477
    [Abstract] [Full Text] [Related]

  • 25. Ertapenem administered as outpatient parenteral antibiotic therapy for urinary tract infections caused by extended-spectrum-beta-lactamase-producing Gram-negative organisms.
    Bazaz R, Chapman AL, Winstanley TG.
    J Antimicrob Chemother; 2010 Jul; 65(7):1510-3. PubMed ID: 20460397
    [Abstract] [Full Text] [Related]

  • 26. Clinical and economic implications of urinary tract infections.
    Steiger SN, Comito RR, Nicolau DP.
    Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):377-383. PubMed ID: 28730918
    [Abstract] [Full Text] [Related]

  • 27. Infective endocarditis due to multidrug resistant gram-negative bacilli: single centre experience over 5 years.
    Durante-Mangoni E, Andini R, Agrusta F, Iossa D, Mattucci I, Bernardo M, Utili R.
    Eur J Intern Med; 2014 Sep; 25(7):657-61. PubMed ID: 24954705
    [Abstract] [Full Text] [Related]

  • 28. Use of hospital resources in ICU inpatients with infections caused by carbapenem-resistant Gram-negative bacteria: A real clinical practice-based study in Spain.
    Ferrer R, Garnacho-Montero J, Rascado P, Contreras S, Cantón-Bulnes L, Barral P, Del Cerro I, Badia X.
    Enferm Infecc Microbiol Clin (Engl Ed); 2023 Mar; 41(3):162-168. PubMed ID: 36610832
    [Abstract] [Full Text] [Related]

  • 29. Healthcare Burden and Costs Associated with Urinary Tract Infections in Type 2 Diabetes Mellitus Patients: An Analysis Based on a Large Sample of 456,586 German Patients.
    Wilke T, Böttger B, Berg B, Groth A, Botteman M, Yu S, Fuchs A, Maywald U.
    Nephron; 2016 Mar; 132(3):215-26. PubMed ID: 26930608
    [Abstract] [Full Text] [Related]

  • 30. Multidrug-resistant gram-negative bloodstream infections among residents of long-term care facilities.
    Venkatachalam I, Yang HL, Fisher D, Lye DC, Moi Lin L, Tambyah P, Perl TM.
    Infect Control Hosp Epidemiol; 2014 May; 35(5):519-26. PubMed ID: 24709720
    [Abstract] [Full Text] [Related]

  • 31. Prospective cohort study on hospitalised patients with suspected urinary tract infection and risk factors por multidrug resistance.
    Garcia-Bustos V, Escrig AIR, López CC, Estellés RA, Jerusalem K, Cabañero-Navalón MD, Massó VM, Sigona-Giangreco IA, Sahuquillo-Arce JM, Hernández IC, Lletí MS.
    Sci Rep; 2021 Jun 07; 11(1):11927. PubMed ID: 34099754
    [Abstract] [Full Text] [Related]

  • 32. Disease burden of urinary tract infections among type 2 diabetes mellitus patients in the U.S.
    Yu S, Fu AZ, Qiu Y, Engel SS, Shankar R, Brodovicz KG, Rajpathak S, Radican L.
    J Diabetes Complications; 2014 Jun 07; 28(5):621-6. PubMed ID: 24929797
    [Abstract] [Full Text] [Related]

  • 33. Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol.
    Dickstein Y, Leibovici L, Yahav D, Eliakim-Raz N, Daikos GL, Skiada A, Antoniadou A, Carmeli Y, Nutman A, Levi I, Adler A, Durante-Mangoni E, Andini R, Cavezza G, Mouton JW, Wijma RA, Theuretzbacher U, Friberg LE, Kristoffersson AN, Zusman O, Koppel F, Dishon Benattar Y, Altunin S, Paul M, AIDA consortium.
    BMJ Open; 2016 Apr 20; 6(4):e009956. PubMed ID: 27098822
    [Abstract] [Full Text] [Related]

  • 34. An institutional perspective on the impact of recent antibiotic exposure on length of stay and hospital costs for patients with gram-negative sepsis.
    Micek S, Johnson MT, Reichley R, Kollef MH.
    BMC Infect Dis; 2012 Mar 13; 12():56. PubMed ID: 22414209
    [Abstract] [Full Text] [Related]

  • 35. Antimicrobial resistance of bacterial isolates from respiratory care wards in Taiwan: a horizontal surveillance study.
    Kuo LC, Yu CJ, Kuo ML, Chen WN, Chang CK, Lin HI, Chen CC, Lu MC, Lin CH, Hsieh WF, Chen LW, Chou Y, Huang MS, Lee CH, Chen SC, Thai SL, Chen PC, Chen CH, Tseng CC, Chen YS, Hsiue TR, Hsueh PR.
    Int J Antimicrob Agents; 2008 May 13; 31(5):420-6. PubMed ID: 18358701
    [Abstract] [Full Text] [Related]

  • 36. Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam.
    Popejoy MW, Long J, Huntington JA.
    BMC Infect Dis; 2017 May 02; 17(1):316. PubMed ID: 28464828
    [Abstract] [Full Text] [Related]

  • 37. Effect of prior receipt of antibiotics on the pathogen distribution and antibiotic resistance profile of key Gram-negative pathogens among patients with hospital-onset urinary tract infections.
    Bidell MR, Opraseuth MP, Yoon M, Mohr J, Lodise TP.
    BMC Infect Dis; 2017 Feb 28; 17(1):176. PubMed ID: 28241755
    [Abstract] [Full Text] [Related]

  • 38. [Clinical and economic expedience of ertapenem therapy of complicated urinary tract infection].
    Kolbin AS, Sidorenko SV, Zagorodnikova KA, Musatov VB, Iakovlev AA.
    Antibiot Khimioter; 2011 Feb 28; 56(1-2):35-42. PubMed ID: 21780670
    [Abstract] [Full Text] [Related]

  • 39. Multi-drug-resistant Gram-negative bacteria causing urinary tract infections: a review.
    Mazzariol A, Bazaj A, Cornaglia G.
    J Chemother; 2017 Dec 28; 29(sup1):2-9. PubMed ID: 29271736
    [Abstract] [Full Text] [Related]

  • 40. The burden of multidrug-resistant organisms on tertiary hospitals posed by patients with recent stays in long-term acute care facilities.
    Marchaim D, Chopra T, Bogan C, Bheemreddy S, Sengstock D, Jagarlamudi R, Malani A, Lemanek L, Moshos J, Lephart PR, Ku K, Hasan A, Lee J, Khandker N, Blunden C, Geffert SF, Moody M, Hiro R, Wang Y, Ahmad F, Mohammadi T, Faruque O, Patel D, Pogue JM, Hayakawa K, Dhar S, Kaye KS.
    Am J Infect Control; 2012 Oct 28; 40(8):760-5. PubMed ID: 22285709
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.